PhOx 430
Alternative Names: PhO-430; PhOx-430Latest Information Update: 28 Jul 2026
At a glance
- Originator Phost'in Therapeutics
- Class Antineoplastics
- Mechanism of Action Glucosyltransferase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Solid-tumours in France (PO)
- 17 Oct 2025 Efficacy, adverse event, pharmacodynamics and pharmacokinetics data from the phase I PhAST trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
- 28 Aug 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (PO)